US FDA commissioner's hammer falls on Avastin; breast cancer use revoked
This article was originally published in SRA
US Food and Drug Administration commissioner Margaret Hamburg has rescinded the agency's approval for Genentech's Avastin (bevacizumab) as a treatment for HER2-negative metastatic breast cancer (MBC), after deciding that follow-up studies had failed to show that the drug is a safe and effective therapy for the disease1.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.